ASE – Real vaqt narxi. Valyuta: USD
1.49
-0.04 (-2.61%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
1.49
0.00 (0.00%)
Bozordan keyin: Mar 27, 2026, 7:47 PM EDT
Lineage Cell Therapeutics, Inc., klinik bosqichdagi biotexnologiya kompaniyasi bo'lib, Qo'shma Shtatlar va xalqaro miqyosda jiddiy tibbiy sharoitlarni davolash uchun hujayra o'rnini bosuvchi terapiyalarni ishlab chiqadi. Kompaniya yoshga bog'liq makula degeneratsiyasini davolash uchun 2a bosqichli klinik sinovda bo'lgan, retinak pigment epitelial hujayralarini o'rnini bosuvchi allogen terapiya OpRegen; va bo'yin umurtqa pog'onasi shikastlanishlarini davolash uchun 1/2a bosqichli ko'p markazli klinik sinovda bo'lgan allogen oligodendrosit progenitor hujayra terapiyasi OPC1 ni ishlab chiqadi. Shuningdek, u sensorinevral eshitish qobiliyatini yo'qotishni davolash uchun preklinik rivojlanishda bo'lgan allogen eshitish nervi progenitor hujayra transplantatsiyasi ReSonance (ANP1); va fotoreseptor disfunktsiyasi yoki shikastlanishi tufayli ko'rish qobiliyatini yo'qotishni davolash uchun preklinik rivojlanishda bo'lgan allogen fotoreseptor hujayra transplantatsiyasi PNC1 ni taklif etadi. Qo'shimcha ravishda, kompaniya noma'lum ko'rsatkichni davolash uchun hujayra transplantatsiyasi nomzodini ishlab chiqish uchun yangi gipoimmün indüklangan pluripotent stam hujayra liniyasi RND1 ni ishlab chiqmoqda, shuningdek, 1-toifa diabetni davolash uchun allogen hujayra transplantatsiyasi ILT1; va LCT-CON, allogen hujayra transplantatsiyasi, shuningdek, retinal kasalliklar, nevrologik kasalliklar, oftalmologiya, metabolik va onkologik kasalliklar uchun terapevtik mahsulotlarni tadqiq qilish va ishlab chiqish bilan shug'ullanadi. Kompaniyaning ReSonance (ANP1) preklinik rivojlanishi uchun William Demant Invest bilan hamkorlik shartnomasi mavjud. Kompaniyaning, shuningdek, kompaniyaning ma'lum bir hujayra transplantatsiyasi mahsuloti nomzodlariga differentsiatsiya qilish uchun foydalanishi uchun genetik muhandislikka ega iPSC liniyasini ishlab chiqish bo'yicha Factor Bioscience Inc. bilan strategik hamkorligi mavjud. Kompaniya ilgari BioTime, Inc. nomi bilan tanilgan va 2019-yil avgust oyida Lineage Cell Therapeutics, Inc. nomini olgan. Lineage Cell Therapeutics, Inc. 1990-yilda tashkil etilgan va Kaliforniyaning Carlsbad shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Charlotte Hubbert Ph.D. | Vice President of Corporate Development |
| Dr. Harold D. Waitz | Vice President of Regulatory Affairs & Quality Control |
| Dr. Rami Skaliter M.Sc., Ph.D. | Chief Executive Officer of Cell Cure Neurosciences |
| Mr. Brian M. Culley M.A., M.B.A. | CEO, President & Director |
| Mr. George A. Samuel III, J.D. | General Counsel & Company Secretary |
| Ms. Alexandra Hernandez | Senior Director of Finance & Controller |
| Ms. Brandi L. Roberts CPA, M.B.A. | Consultant |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-11 | S-3 | lctx-20260311.htm |
| 2026-03-05 | 10-K | lctx-20251231.htm |
| 2025-11-28 | 8-K | lctx-20251128.htm |
| 2025-11-24 | 8-K | lctx-20251120.htm |
| 2025-11-06 | 10-Q | lctx-20250930.htm |
| 2025-08-26 | 8-K | lctx-20250826.htm |
| 2025-08-15 | S-8 | lctx-20250815.htm |
| 2025-08-12 | 10-Q | lctx-20250630.htm |
| 2025-07-02 | 8-K | lctx-20250626.htm |
| 2025-06-23 | 8-K | lctx-20250623.htm |
| Ms. Ioana C. Hone | Director of Investor Relations |
| Ms. Jill Ann Howe | CFO & Principal Financial and Accounting Officer |